SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

31 Oct 2023 Evaluate
The company witnessed a 8.67% growth in the revenue at Rs. 24533.45 millions for the quarter ended September 2023 as compared to Rs. 22575.49 millions during the year-ago period.A humble growth in net profit of 12.53% reported in the quarter ended September 2023 to Rs. 4728.85  millions from Rs. 4202.32 millions.Operating profit for the quarter ended September 2023 rose to 6933.12 millions as compared to 5914.84 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 24533.45 22575.49 8.67 47535.56 43188.00 10.07 81271.53 74862.22 8.56
Other Income 581.18 691.47 -15.95 1155.54 879.23 31.43 1627.83 2038.14 -20.13
PBIDT 6933.12 5914.84 17.22 12902.17 10306.45 25.19 18601.64 20418.85 -8.90
Interest 43.10 81.90 -47.37 62.78 176.19 -64.37 277.48 471.21 -41.11
PBDT 6890.02 5832.94 18.12 12839.39 10130.26 26.74 18324.16 19947.64 -8.14
Depreciation 770.39 660.40 16.66 1455.82 1312.61 10.91 2695.80 1233.27 118.59
PBT 6119.63 5172.54 18.31 11383.57 8817.65 29.10 15628.36 18714.37 -16.49
TAX 1390.78 970.22 43.35 2561.89 1633.69 56.82 3145.79 4820.13 -34.74
Deferred Tax 168.24 77.75 116.39 246.97 196.68 25.57 229.43 529.79 -56.69
PAT 4728.85 4202.32 12.53 8821.68 7183.96 22.80 12482.57 13894.24 -10.16
Equity 400.59 400.59 0.00 400.59 400.59 0.00 400.59 400.59 0.00
PBIDTM(%) 28.26 26.20 7.86 27.14 23.86 13.74 22.89 27.28 -16.08

Mankind Pharma Share Price

2123.20 18.50 (0.88%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×